CIK 0001622229 · Large accelerated filer
Cogent Biosciences, Inc.
Sign in to watch- Ticker
- COGT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465308248
- Phone
- 617-945-5576
- Business address
- 180 THIRD AVENUE, 4TH FLOOR, WALTHAM, MA
- Former names
- Unum Therapeutics Inc., Unum Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,689,493
- in 1 filing, $1.7M under 10b5-1 plans
Net −$1,689,493. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-01-23 | Green John L. Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2025-01-23 | Pinnow Cole Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +240,000 | 240,000 | ||
| 2025-01-23 | Robinson John Edward Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2025-01-23 | Sachs Jessica Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +270,000 | 270,000 | ||
| 2025-01-23 | Robbins Andrew R President and CEO | Grant or award · Stock Option (Right to Buy) | +915,000 | 915,000 | ||
| 2025-01-23 | Kearns Evan Chief Legal Officer | Grant or award · Stock Option (Right to Buy) | +230,000 | 230,000 | ||
| 2025-01-14 | Pinnow Cole Chief Commercial Officer | Purchase | +43,750 | $7.60 | $332K | 45,848 |
| 2025-01-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,785 | 2,785 | ||
| 2024-10-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,034 | 2,034 | ||
| 2024-07-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +2,462 | 2,462 | ||
| 2024-06-10 | Fairmount Funds Management LLC Director | Option exercise | +1,500,000 | 6,225,641 | ||
| 2024-06-10 | Fairmount Funds Management LLC Director | Option exercise · Series B Convertible Preferred Stock | −1,500 | 0 | ||
| 2024-06-05 | CAIN CHRISTOPHER W. Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2024-06-05 | Ros Matthew Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2024-06-05 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2024-06-05 | Harwin Peter Evan Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2024-06-05 | Shegog Todd Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2024-06-05 | Morris Arlene Director | Grant or award · Stock Option (Right to Buy) | +44,700 | 44,700 | ||
| 2024-05-25 | Pinnow Cole Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +525,000 | 525,000 | ||
| 2024-04-01 | Ferrante Karen Jean Director | Grant or award · Stock Option (Right to Buy) | +3,213 | 3,213 |
Page 4 of 7 · 131 trades